Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

Canada NewsWire February 14, 2020

Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

Business Wire February 6, 2020

Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019

Business Wire January 29, 2020

Bioasis Technologies Inc. Announces Warrant Extension and Repricing

Business Wire January 29, 2020

Bioasis Announces Shares for Debt Transaction

Business Wire January 6, 2020

Bioasis to Present at Upcoming Industry Conferences

Business Wire January 6, 2020

Bioasis Completes Bridge Financing Transaction

Business Wire December 23, 2019

Bioasis Announces Bridge Financing

Business Wire December 16, 2019

Bioasis Announces Annual General Meeting Results

Business Wire December 5, 2019

Bioasis Appoints Consultant Chief Medical Officer and Nominates Medical Oncology Advisory Board

Business Wire December 4, 2019

Bioasis to Host Annual General Meeting Webcast on December 5, 2019

Business Wire November 27, 2019

Bioasis Announces Director Resignation

Business Wire November 25, 2019

Bioasis Announces Issuance of Japanese Patent Relating to xB3(TM) Platform Technology for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier

Business Wire November 14, 2019

Bioasis Completes Financing Transactions

Business Wire November 8, 2019

Bioasis Announces Bridge Financing

Business Wire October 28, 2019

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending August 31, 2019

Business Wire October 25, 2019

Bioasis Announces Proposed Private Placement

Business Wire September 23, 2019

Bioasis Announces Allowance of Patent Application in Japan Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

Business Wire September 10, 2019

Bioasis Announces Stock Option Grants

Business Wire August 29, 2019

Bioasis Announces Registration and Grant Notice of Patent Application in China Relating to xB3 Platform Technology for the Delivery of Therapeutic Agents Across the Blood-Brain Barrier

Business Wire August 21, 2019